A Cost-Effectiveness Analysis of Biosimilar Infliximab (Inflectra ®) For The Treatment of Ankylosing Spondylitis In Nine European Countries
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1124
https://www.valueinhealthjournal.com/article/S1098-3015(16)32490-1/fulltext
Title :
A Cost-Effectiveness Analysis of Biosimilar Infliximab (Inflectra ®) For The Treatment of Ankylosing Spondylitis In Nine European Countries
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32490-1&doi=10.1016/j.jval.2016.09.1124
First page :
A540
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1055